SB 72, also known as the “Hope for Georgia Patients Act,” expands access to investigational treatments for patients with severely debilitating or life-threatening illnesses. The bill builds on Georgia’s existing Right to Try Act by allowing patients to seek personalized, experimental medical treatments not fully approved by the U.S. Food & Drug Administration (FDA). While the bill could expand access to experimental treatments for patients with rare or terminal diseases, it also opens the door to further expansion of access to treatments not approved by the FDA. FDA approval ensures that drugs meet strict safety and efficacy standards, and bypassing this process could expose patients to unknown risks. Additionally, patients may pursue costly, unproven treatments that may not work or could worsen their condition.